Prof. Dr. med. H. Günter Derigs

Zertifikate

ESMO-Examen

Veröffentlichungen

Publikationen:

1. Hess G, Flohr T, Kolbe K, Bonn S, Schuler M, Derigs HG, Huber C (2006). Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin`s lymphoma. Ann Hematol. 85:769-79.

2. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J. (2006). High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 24:3865-70.

3. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C; European Germ Cell Cancer Consensus Group. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 15:1377-99.

4. Kroger N, Damon L, Zander AR, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti G; Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation; German Adjuvant Breast Cancer Study Group; University of California, San Francisco. (2003) Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transplant. 32:1153-7

5. Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, Lippert C, Koser M, Stockamp K, Otto C, Melchior H, Fassmann C, Potratz C, Loch T, Derigs HG, Becker T, Kalble T, Piechota HJ, Hertle L, Weinknecht S, Weissbach L, Al-Mwalad M, Hamza A, Henss H, Brkovic D, Pomer S, Roloff J, Walz P, Muschter R, Tunn U, Winter E, Bub P, Kaldenbach U, Roth S, Brauers A, Jakse G, Richter AE, Wirth M, Hartlapp J, Van Ahlen H, Stockle M. (2003). Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany Urologe A. 42:1074-86

6. Kroger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schafer-Eckart K, Wittkowsky G, Schmitz N, Kruger W, Zabelina T, Renges H, Ayuk F, Krull A, Zander A; German Study-group Multiple Myeloma (DSMM). (2003). Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM). Bone Marrow Transplant. 31:973-9.

7. Hess, G., Flohr, T., Huber, C., Kolbe, K., Derigs, H. G., und Fischer, T. (2003). Safety aand feasability of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin’s lymphoma. Bone Marrow Transplant 31, 775-82

8. Flohr, T., Hess, G., Kolbe, K., Gamm, H., Nolte, H., Stanislawski, T., Huber, C. und Derigs, H. G. (2002). Rituximab in vivo purging is safe and effcive in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 29, 769-75

9. Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schoffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C. (2002) Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 20, 2031-7.

10. Kuball J, Derigs HG, Wolfel T. (2002) [T-cell therapy in oncology. Therapeutic vaccination, allogeneic blood stem cell transplantation and adoptive T-cell transfer] Dtsch Med Wochenschr. 127, 755-62.

11. Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neureither S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs G, Gerl A, Berdel WE, Kanz L, Siegert W. (2001) Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol. 19, 81-8.

12. Foncuberta, M.C., Cagnoni, P.J., Brandts, C.H., Mandanas, R., Fields, K., Derigs, H.G., Reed, E., Sonis, S.T., Fay, J., LeVeque, F., Pouillart, P., Schrezenmeier, H., Emmons, R. und Thiel, E. (2001). Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. J Immunother, 24, 384-388.

13. Kreiter, S., Winkelmann, N., Schneider, P.M., Schuler, M., Fischer, T., Ullmann, A.J., Huber, C., Derigs, H.G. und Kolbe, K. (2001). Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation. Bone Marrow Transplant, 28, 157-161.

14. Rick.O, Bokemeyer, C., Beyer, J., Hartmann, J.T., Schwella, N., Kingreen, D.N.S., Casper, J., Wandt, H., Hartmann, F., Schmoll, H., Derigs, G., Gerl, A., Berdel, W., Kanz, L. und Siegert, W. (2001). Salvage treatment with Paclitaxel, Ifosfamide, and Cisplatin plus high-dose Carboplatin, Etoposide, and Thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Ocol, 19, 81-88.

15. Kreiter S, Wehler T, Landt O, Huber C, Derigs HG, Hess G. (2000) Rapid identification of minor histocompatibility antigen HA-1 subtypes H and R using fluorescence-labeled oligonucleotides. Tissue Antigens. 56, 449-52.

16. Derigs, H.G. (2000). In vitro and in vivo purging of B lymphoma cells from stem cell products using anti-CD20 antibodies. Cytotherapy, 2, 445-453.

17. Heussel, C.P., Kauczor, H.U., Heussel, G., Derigs, H.G. und Thelen, M. (2000). Focussuche bei neuropenischem Fieber: Bildgebende Diagnostik. Radiologe, 40, 88-101.

18. Kollmannsberger, C., Nichols, C., Bamberg, M., Hartmann, J.T., Schleucher, N., Beyer, J., Schofski, P., Derigs, G., Ruther, U., Bohlke, I., Schmoll, H.J., Kanz, L. und Bokemeyer, C. (2000). First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases . Ann Oncol, 11, 553-559.

19. Bokemeyer, C., Hartmann, J.T., Mayer, F., Bohlke, I., Kanz, L., Von Pawel, J., Derigs, G. und Schroder, M. (2000). UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors. Oncology (Huntingt), 14, 63-67.

20. Craddock, C., Bardy, P., Kreiter, S., Johnston, R., Apperley, J., Marks, D., Huber, C., Kolbe, K., Goulding, R., Lawler, M., Goldman, J., Hughes, T. und Derigs, G. (2000). Short Report: Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. Br J Haematol, 111, 797-800.

21. Despres, D., Flohr, T., Uppenkamp, M., Baldus, M., Hoffmann, M., Huber, C. und Derigs, H.G. (2000). CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device [In Process Citation]. J Hematother Stem Cell Res, 9, 557-564.

22. Heussel, C.P., Kauczor, H.U., Heussel, G., Derigs, H.G. und Thelen, M. (2000). Focussuche bei neuropenischem Fieber: Bildgebende Diagnostik. Radiologe, 40, 88-101.

23. Kollmannsberger, C., Nichols, C., Bamberg, M., Hartmann, J.T., Schleucher, N., Beyer, J., Schofski, P., Derigs, G., Ruther, U., Bohlke, I., Schmoll, H.J., Kanz, L. und Bokemeyer, C. (2000). First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases . Ann Oncol, 11, 553-559.

24. Derigs, H.G. (1999). Polycythaemie vera. Medizinische Welt, 50, 67-72.

25. Gollner, G., Bug, G., Rupilius, B., Peschel, C., Huber, C. und Derigs, H.G. (1999). Regulatory elements of the leukaemia inhibitory factor (LIF) promoter in murine bone marrow stromal cells. Cytokine, 11, 656-663.

26. Ostermann, H., Derigs, H.G., Heussel, G., Kern, W.V., Kiehl, M., Kienast, J., Mesters, R., Schiel, X., Schumann, R.R. und Weiss, M. (1999). Sepsis in der Neutropenie. Standard Empfehlungen der Arbeitsgruppe Infektionen in Hämatologie und Onkologie in der Deutschen Gesellschaft für Hämatologie und Onkologie. Dtsch Med Wochenschr, 124 Suppl 1, S14-S17

27. Bokemeyer, C., Harstrick, A., Beyer, J., Metzner, B., Ruther, U., Hartmann, J.T., Holstein, K., Derigs, H.G., de Wit, R., Casper, J., Schoffski, P., Kuhrer, I., Illiger, H.J., Kempf, B., Reichle, A., Foller, A., Hossfeld, D.K., Fischer, J.T., Berdel, W.E., Gerhartz, H.H., Kirchner, H., Pfluger, K.H., Ostermann, H., Kanz, L. und Schmoll, H.J. (1998). The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Semin Oncol, 25, 24-32.

28. Bokemeyer, C., Harstrick, A., Beyer, J., Metzner, B., Rüther, U., Hartmann, J.T., Holstein, K., Derigs, H.G., de Wit, R., Casper, J., Schöffski, P., Kührer, I., Illiger, H.-J., Kempf, B., Reichle, A., Föller, A., Hossfeld, D.K., Fischer, J.Th., Berdel, W., Gerhartz, H., Kirschner, H., Pflüger, K., Ostermann, H., Kanz, L. und Schmoll, H.-J. (1998). First-line high-dose chemotherapy for `poor risk` metastatic non-seminomatous testicular germ cell tumors. Onkologie, 21 (suppl 2), 23-25.

29. Bug, G., Aman, J., Huber, C., Peschel, C. und Derigs, H.G. (1998). cAMP analogues downregulate the expression of granulocyte macrophage colony-stimulating factor (GM-CSF) in human bone marrow stromal cells in vitro. Mediators Inflamm, 7, 195-199.

30. Fischer, T., Neubauer, A., Mohm, J., Huhn, D., Busemann, C., Link, H., Arseniev, L., Bussing, B., Novotny, J., Ganser, A., Duyster, J., Bunjes, D., Westermeier, T., Flohr, T., Despres, D., Gamm, H., Decker, J., Derigs, G., Aulitzky, W. und Huber, C. (1998). Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied. Ann Hematol, 77, 21-26.

31. Kolbe, K., Peschel, C., Rupilius, B., Despres, D., Burger, K., Sklenar, I., Farber, L., Huber, C. und Derigs, H.G. (1997). Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients. Bone Marrow Transplant, 20, 1027-1032.

32. Kolbe, K., Domkin, D., Derigs, H.G., Bhakdi, S., Huber, C. und Aulitzky, W.E. (1997). Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant, 19, 143-147.

33. Oberholzer, K., Kauczor, H.U., Heussel, C.P., Derigs, G. und Thelen, M. (1997). Klinische Relevanz der NNH-Computertomographie vor der Knochenmarktransplantation. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr, 166, 493-497.

34. Derigs, H.G., Huber, C., Mahlke, M. und Kolbe, K. (1996). Die Hochdosischemotherapie in der Behandlung des Mammakarzinoms. Geburtshilfe und Frauenheilkunde, 56, 190-197.

35. Derigs, H.G., Morgan, D.A., Hoffman, R., Litz, S.L., Srour, E.F., Brandt, J.E. und Boswell, H.S. (1995). AP-1/C-JUN and C-MYC regulation during megakaryocytic differentiation of a human bi-potential growth-factor-dependent cell line. PLATELETS, 6, 24-30.

36. Gollner, G., Aman, M.J., Steffens, H.P., Huber, C., Peschel, C. und Derigs, H.G. (1995). Interferon-alpha (IFN-alpha) inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF) expression at the post-transcriptional level in murine bone marrow stromal cells. Br J Haematol, 91, 8-14.

37. Schwab, R., Peschel, C., Despres, D., Derigs, G., Fischer, T., Huber, C. und Aulitzky, W.E. (1995). Deficient cell cycle control in myeloid cells of patients with newly diagnosed chronic myeloid leukemia. Cytokines Mol Ther, 1, 281-288.

38. Aman, M.J., Keller, U., Derigs, G., Mohamadzadeh, M., Huber, C. und Peschel, C. (1994). Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood, 84, 4142-4150.

39. Derigs, H.G., Reifel-Miller, A., Kaushansky, K., Hromas, R.A. und Boswell, H.S. (1994). Granulocyte-macrophage colony-stimulating factor expression is regulated at transcriptional and posttranscriptional levels in a murine bone marrow stromal cell line. Exp Hematol, 22, 924-932.

40. Derigs, H.G., Schmoll, H.-J. und Huber, C. (1994). Therapiestrategien bei nichtseminomatösen Hodentumoren. Dtsch Med Wochenschr, 119, 156-164.

41. Derigs, H.G., Reifel-Miller, A., Kaushansky, K., Hromas, R.A. und Boswell, H.S. (1994). GM-CSF expression is regulated at transcriptional and posttranscriptional levels in a murine bone marrow stromal cell line. Experimental Hematology, 22, 924-932.

42. Keller, U., Aman, M.J., Derigs, G., Huber, C. und Peschel, C. (1994). Human interleukin-4 enhances stromal cell-dependent hematopoiesis: costimulation with stem cell factor. Blood, 84, 2189-2196.

43. Derigs, H.G. und Boswell, H.S. (1993). LIF mRNA expression is transcriptionally regulated in murine bone marrow stromal cells. Leukemia, 7, 630-634.

44. Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G. und Schneider, W. (1992). Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia, 6, 52-59.

45. Straneva, J.E., van Besien, K.W., Derigs, G. und Hoffman, R. (1992). Is interleukin 6 the physiological regulator of thrombopoiesis? Exp Hematol, 20, 47-50.

46. Boswell, H.S., Derigs, H.G., Nahreini, T.S. und Burgess, G.S. (1991). Paracrine interactions govern the progression of lymphohemopoietic malignancies: Evidence from long-term marrow cultures. In W.R. Paukovits (Herausgeber). Growth regulation and carcinogenesis Volume 1 (1 ed.) (pp. 251-265). Boca Raton, Ann Arbor, Boston: CRC Press

47. Derigs, H.G., Nahreini, T.S., Harrington, M.A., Burgess, G.S., English, D., Inhorn, L., Gabig, T.G. und Boswell, H.S. (1991). Ras oncogene mediates paracrine interactions between leukemic progenitor cells and stromal elements. In W.R. Paukovits (Herausgeber). Growth regulation and carcinogenesis Volume 1 (1 ed.) (pp. 267-278). Boca Raton, Ann Arbor, Boston: CRC Press

48. Derigs, H.G., Burgess, G.S., Klingberg, D., Nahreini, T.S., Mochizuki, D.Y., Williams, D.E. und Boswell, H.S. (1990). Role for cyclic AMP in the postreceptor control of cytokine-stimulated stromal cell growth factor production. Leukemia, 4, 471-479.

49. Girasole, G., Sakagami, Y., Hustmyer, F.G., Yu, X.P., Derigs, H.G., Boswell, S., Peacock, M., Boder, G. und Manolagas, S.C. (1990). 17-beta estradiol inhibits cytokine induced IL-6 production by bone marrow stromal cells and osteoblasts. Journal of Bone and Mineral Research, 5, Suppl.2, S273(Abstract)

50. Heyll, A. und Derigs, G. (1990). Chronic myelomonocytic leukemia: clinical data, morphological features, and outcome in 56 patients. Hamatol Bluttransfus, 33, 387-391.

51. Boswell, H.S., Harrington, M.A., Burgess, G.S., Nahreini, T.L., Derigs, H.G., Hodges, T.D., English, D., Crean, C.D. und Gabig, T.G. (1989). A mutant RAS gene acts through protein kinase C to augment interleukin-3 dependent proliferation in a fastidious immortal myeloid cell line. Leukemia, 3, 662-668.

52. Derigs, H.G., Klingberg, D., Tricot, G.J. und Boswell, H.S. (1989). Effector function for RAS oncogene in interleukin-3-dependent myeloid cells involves diminished efficacy of prostaglandin E1-mediated inhibition of proliferation. Blood, 74, 1942-1951.

53. Aul, C., Derigs, G. und Schneider, W. (1988). Diagnostic and prognostic significance of serum thymidine kinase in the myelodysplastic syndromes. J Clin Exp Hematol, 57, 233-233.

54. Derigs, H.G., Aul, C., Heyll, A. und Schneider, W. (1987). Serum deoxythymidine kinase in patients with myelodysplasia. Blut, 55, 307

55. Derigs, H.G., Oehr, P., Weissbach, L., Hartlap, J., Jaeger, N. und Labetzki, L. (1985). Vergleich von AFP, beta-HCG, TPA mit konventionellen klinischen Methoden bei Krankheitsverlaeufen von Hodentumorpatienten. TumorDiagnostik und Therapie, 6, 68-73.

56. Oehr, P., Weissbach, L., Figge, M. und Derigs, H.G. (1983). Vergleich von Sensitivitaet und Spezifitaet von beta-HCG bei Patienten mit Hodenmalignomen. Beitr Urol, 3, 268-272.

57. Oehr, P., Weissbach, L., Figge, M. und Derigs, G. (1983). Specificity and sensitivity of human chorionic gonadotropin radioimmunoassays. A comparison of two different approaches. Urol Int, 38, 213-218.

58. Oehr, P., Weissbach, L., Figge, M. und Derigs, H.G. (1983). Specifity and sensitivity of human chorionic gonadotropin radioimmunassays. Urol Int, 38, 213-218.

59. Oehr, P., Wustrow, A., Derigs, H.G. und Bormann, R. (1981). Evaluation and characterization of tumor-associated antigens by the inverse distribution function. TumorDiagnostik, 2, 195-198.

60. Oehr, P., Derigs, H.G. und Altmann, R. (1981). Evaluation and characterization of tumor-associated antigens by conversion of inverse distribution function values into specific-sensitivity. TumorDiagnostik, 2, 283-290.

61. Oehr, P., Adolphs, H.-D., Wustrow, A. und Derigs, H.G. (1981). Comparision of mono- and polyclonal antibodies in plasma and CEA-determination. TumorDiagnostik, 2, 189-194.